3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Prostatic Neoplasms
4
Neoplasm Metastasis
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Ovarian Neoplasms
2
Neoplasms
2
Leukemia, Myeloid, Chronic-Phase
2
Glioblastoma
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Brain Neoplasms
2
Vaping
1
Urinary Bladder Neoplasms
1
Tobacco Use Disorder
1
Stomach Neoplasms
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Peripheral Nervous System Diseases
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Oligodendroglioma
1
Neoplasms by Histologic Type
1
NSCLC
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Lymphoma, T-Cell, Cutaneous
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid
1
Leukemia
1
Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
1
Hematologic Diseases
1
Interventions
Cyclophosphamide
344
Cytarabine
281
fludarabine phosphate
201
Methotrexate
185
Filgrastim
159
Busulfan
147
Etoposide
135
Peripheral Blood Stem Cell Transplantation
133
fludarabine
127
Rituximab
119
Radiotherapy
111
Vincristine
102
Cyclosporine
98
Daunorubicin
96
Antilymphocyte Serum
94
Dexamethasone
91
Tacrolimus
85
Mycophenolic Acid
85
Whole-Body Irradiation
80
Melphalan
79
Idarubicin
67
Mercaptopurine
66
Imatinib Mesylate
66
Granulocyte Colony-Stimulating Factor
65
Azacitidine
65
Methylprednisolone
59
Prednisone
58
Doxorubicin
58
Clofarabine
54
sargramostim
53
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Leukemia
×
BID protein, human
×
Clear all
NCT02627677
2021-11-26
OPTIC-2L
Takeda
Phase 3
Terminated
44 enrolled
22 charts